Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer

  • Authors:
    • Mitsuro Kanda
    • Dai Shimizu
    • Tsutomu Fujii
    • Haruyoshi Tanaka
    • Masahiro Shibata
    • Naoki Iwata
    • Masamichi Hayashi
    • Daisuke Kobayashi
    • Chie Tanaka
    • Suguru Yamada
    • Goro Nakayama
    • Hiroyuki Sugimoto
    • Masahiko Koike
    • Michitaka Fujiwara
    • Yasuhiro Kodera
  • View Affiliations

  • Published online on: June 17, 2016     https://doi.org/10.3892/ijo.2016.3584
  • Pages: 1195-1202
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Identification of novel gastric cancer (GC)-related molecules is necessary to improve management of patients with GC in both diagnostic and therapeutic aspects. The aim of the present study was to determine whether protein arginine methyltransferase 5 (PRMT5) acts as an oncogene in the progression of GC and whether it serves as a novel diagnostic marker and therapeutic target. We conducted global expression profiling of GC cell lines and RNA interference experiments to evaluate the effect of PRMT5 expression on the phenotype of GC cells. We analysed tissues of 179 patients with GC to assess the association of PRMT5 mRNA levels with clinicopathological factors. Differential expression of PRMT5 mRNA by GC cell lines correlated positively with the levels of GEMIN2, STAT3 and TGFB3. PRMT5 knockdown reduced the proliferation, invasion and migration of a GC cell line. PRMT5 mRNA levels were significantly higher in GC tissues than the corresponding adjacent normal tissues and were independent of tumour depth, differentiation and lymph node metastasis. High PRMT5 expression was an independent risk factor of positive peritoneal lavage cytology (odds ratio 3.90, P=0.003) and decreased survival. PRMT5 enhances the malignant phenotype of GC cell lines and its expression in gastric tissues may serve as a biomarker for patient stratification and a potential target of therapy.
View Figures
View References

Related Articles

Journal Cover

September 2016
Volume 49 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Kanda, M., Shimizu, D., Fujii, T., Tanaka, H., Shibata, M., Iwata, N. ... Kodera, Y. (2016). Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer. International Journal of Oncology, 49, 1195-1202. https://doi.org/10.3892/ijo.2016.3584
MLA
Kanda, M., Shimizu, D., Fujii, T., Tanaka, H., Shibata, M., Iwata, N., Hayashi, M., Kobayashi, D., Tanaka, C., Yamada, S., Nakayama, G., Sugimoto, H., Koike, M., Fujiwara, M., Kodera, Y."Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer". International Journal of Oncology 49.3 (2016): 1195-1202.
Chicago
Kanda, M., Shimizu, D., Fujii, T., Tanaka, H., Shibata, M., Iwata, N., Hayashi, M., Kobayashi, D., Tanaka, C., Yamada, S., Nakayama, G., Sugimoto, H., Koike, M., Fujiwara, M., Kodera, Y."Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer". International Journal of Oncology 49, no. 3 (2016): 1195-1202. https://doi.org/10.3892/ijo.2016.3584